Clinical utility of liquid biopsy and integrative genomic profiling in early-stage and oligometastatic cancer patients treated with radiotherapy.
British Journal Of Cancer
Cifuentes, Guadalupe A GA; Santiago, Adrián A; Méndez Blanco, Lucía L; Fueyo, María M; López Martínez, Esther E; Soria, Raquel R; Martín López, Irene I; Cucarella Beltrán, Pepa P; Pardo-Coto, Pablo P; Rodriguez-Rubi, David D; Urquilla, Karla K; Durán, Noelia S NS; Álvarez, Rebeca R; Lago, Claudia G CG; Otero, Andrea A; Diñeiro, Marta M; Capín, Raquel R; Cadiñanos, Juan J; Cabanillas, Rubén R
Publication Date: 2022-12-22
Variant appearance in text: PIK3CA: 328G>A; Glu110Lys
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Frontiers In Endocrinology
Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Cancer Medicine
Sivapiragasam, Abirami A; Ashok Kumar, Prashanth P; Sokol, Ethan S ES; Albacker, Lee A LA; Killian, Jonathan K JK; Ramkissoon, Shakti H SH; Huang, Richard S P RSP; Severson, Eric A EA; Brown, Charlotte A CA; Danziger, Natalie N; McGregor, Kimberly K; Ross, Jeffrey S JS
Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.
Gastric Cancer : Official Journal Of The International Gastric Cancer Association And The Japanese Gastric Cancer Association
Hescheler, Daniel A DA; Plum, Patrick S PS; Zander, Thomas T; Quaas, Alexander A; Korenkov, Michael M; Gassa, Asmae A; Michel, Maximilian M; Bruns, Christiane J CJ; Alakus, Hakan H
Clinical Implication of Concordant or Discordant Genomic Profiling between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer.
Cancer Research And Treatment
Choi, Jung Yoon JY; Choi, Sunho S; Lee, Minhyeok M; Park, Young Soo YS; Sung, Jae Sook JS; Chang, Won Jin WJ; Kim, Ju Won JW; Choi, Yoon Ji YJ; Kim, Jin J; Kim, Dong-Sik DS; Lee, Sung-Ho SH; Seok, Junhee J; Park, Kyong Hwa KH; Kim, Seon Hahn SH; Kim, Yeul Hong YH
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
International Journal Of Cancer
Myers, Andrea P AP; Konstantinopoulos, Panagiotis A PA; Barry, William T WT; Luo, Weixiu W; Broaddus, Russell R RR; Makker, Vicky V; Drapkin, Ronny R; Liu, Joyce J; Doyle, Austin A; Horowitz, Neil S NS; Meric-Bernstam, Funda F; Birrer, Michael M; Aghajanian, Carol C; Coleman, Robert L RL; Mills, Gordon B GB; Cantley, Lewis C LC; Matulonis, Ursula A UA; Westin, Shannon N SN
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
Journal Of Thoracic Oncology : Official Publication Of The International Association For The Study Of Lung Cancer
Langer, Corey J CJ; Redman, Mary W MW; Wade, James L JL; Aggarwal, Charu C; Bradley, Jeffrey D JD; Crawford, Jeffrey J; Stella, Philip J PJ; Knapp, Mark H MH; Miao, Jieling J; Minichiello, Katherine K; Herbst, Roy S RS; Kelly, Karen K; Gandara, David R DR; Papadimitrakopoulou, Vassiliki A VA
Circulating tumour-derived DNA in metastatic soft tissue sarcoma.
Oncotarget
Eastley, Nicholas C NC; Ottolini, Barbara B; Neumann, Rita R; Luo, Jin-Li JL; Hastings, Robert K RK; Khan, Imran I; Moore, David A DA; Esler, Claire P CP; Shaw, Jacqueline A JA; Royle, Nicola J NJ; Ashford, Robert U RU
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Nature Communications
Chen, Fengju F; Zhang, Yiqun Y; Bossé, Dominick D; Lalani, Aly-Khan A AA; Hakimi, A Ari AA; Hsieh, James J JJ; Choueiri, Toni K TK; Gibbons, Don L DL; Ittmann, Michael M; Creighton, Chad J CJ
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
Molecular Cancer Therapeutics
Ganesan, Prasanth P; Moulder, Stacy S; Lee, J Jack JJ; Janku, Filip F; Valero, Vicente V; Zinner, Ralph G RG; Naing, Aung A; Fu, Siqing S; Tsimberidou, Apostolia M AM; Hong, David D; Stephen, Bettzy B; Stephens, Philip P; Yelensky, Roman R; Meric-Bernstam, Funda F; Kurzrock, Razelle R; Wheler, Jennifer J JJ
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Bmc Cancer
Wiegand, Kimberly C KC; Hennessy, Bryan T BT; Leung, Samuel S; Wang, Yemin Y; Ju, Zhenlin Z; McGahren, Mollianne M; Kalloger, Steve E SE; Finlayson, Sarah S; Stemke-Hale, Katherine K; Lu, Yiling Y; Zhang, Fan F; Anglesio, Michael S MS; Gilks, Blake B; Mills, Gordon B GB; Huntsman, David G DG; Carey, Mark S MS
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
Cell Reports
Janku, Filip F; Hong, David S DS; Fu, Siqing S; Piha-Paul, Sarina A SA; Naing, Aung A; Falchook, Gerald S GS; Tsimberidou, Apostolia M AM; Stepanek, Vanda M VM; Moulder, Stacy L SL; Lee, J Jack JJ; Luthra, Rajyalakshmi R; Zinner, Ralph G RG; Broaddus, Russell R RR; Wheler, Jennifer J JJ; Kurzrock, Razelle R
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Molecular Cancer Therapeutics
Ganesan, Prasanth P; Janku, Filip F; Naing, Aung A; Hong, David S DS; Tsimberidou, Apostolia M AM; Falchook, Gerald S GS; Wheler, Jennifer J JJ; Piha-Paul, Sarina A SA; Fu, Siqing S; Stepanek, Vanda M VM; Lee, J Jack JJ; Luthra, Rajyalakshmi R; Overman, Michael J MJ; Kopetz, E Scott ES; Wolff, Robert A RA; Kurzrock, Razelle R
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
Cancer Discovery
Lui, Vivian W Y VW; Hedberg, Matthew L ML; Li, Hua H; Vangara, Bhavana S BS; Pendleton, Kelsey K; Zeng, Yan Y; Lu, Yiling Y; Zhang, Qiuhong Q; Du, Yu Y; Gilbert, Breean R BR; Freilino, Maria M; Sauerwein, Sam S; Peyser, Noah D ND; Xiao, Dong D; Diergaarde, Brenda B; Wang, Lin L; Chiosea, Simion S; Seethala, Raja R; Johnson, Jonas T JT; Kim, Seungwon S; Duvvuri, Umamaheswar U; Ferris, Robert L RL; Romkes, Marjorie M; Nukui, Tomoko T; Kwok-Shing Ng, Patrick P; Garraway, Levi A LA; Hammerman, Peter S PS; Mills, Gordon B GB; Grandis, Jennifer R JR
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Cancer Research
Janku, Filip F; Wheler, Jennifer J JJ; Naing, Aung A; Falchook, Gerald S GS; Hong, David S DS; Stepanek, Vanda M VM; Fu, Siqing S; Piha-Paul, Sarina A SA; Lee, J Jack JJ; Luthra, Rajyalakshmi R; Tsimberidou, Apostolia M AM; Kurzrock, Razelle R
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
Cancer Research
Stemke-Hale, Katherine K; Gonzalez-Angulo, Ana Maria AM; Lluch, Ana A; Neve, Richard M RM; Kuo, Wen-Lin WL; Davies, Michael M; Carey, Mark M; Hu, Zhi Z; Guan, Yinghui Y; Sahin, Aysegul A; Symmans, W Fraser WF; Pusztai, Lajos L; Nolden, Laura K LK; Horlings, Hugo H; Berns, Katrien K; Hung, Mien-Chie MC; van de Vijver, Marc J MJ; Valero, Vicente V; Gray, Joe W JW; Bernards, René R; Mills, Gordon B GB; Hennessy, Bryan T BT